Successfully Accelerating Translational Research at an Academic Medical Center: The University of Michigan-Coulter Translational Research Partnership Program
dc.contributor.author | Pienta, Kenneth J. | en_US |
dc.date.accessioned | 2011-01-31T17:34:52Z | |
dc.date.available | 2012-02-21T18:47:01Z | en_US |
dc.date.issued | 2010-12 | en_US |
dc.identifier.citation | Pienta, Kenneth J.; (2010). "Successfully Accelerating Translational Research at an Academic Medical Center: The University of Michigan-Coulter Translational Research Partnership Program." Clinical and Translational Science 3(6): 316-318. <http://hdl.handle.net/2027.42/79157> | en_US |
dc.identifier.issn | 1752-8054 | en_US |
dc.identifier.issn | 1752-8062 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/79157 | |
dc.description.abstract | Translational research encompasses the effective movement of new knowledge and discoveries into new approaches for prevention, diagnosis, and treatment of disease. There are many roadblocks to successful bench to bedside research, but few have received as much recent attention as the “valley of death.” The valley of death refers to the lack of funding and support for research that moves basic science discoveries into diagnostics, devices, and treatments in humans, and is ascribed to be the result of companies unwilling to fund research development that may not result in a drug or device that will be utilized in the clinic and conversely, the fact that researchers have no access to the funding needed to carry out preclinical and early clinical development to demonstrate potential efficacy in humans. The valley of death also exists because bridging the translational gap is dependent on successfully managing an additional four risks: scientific, intellectual property, market, and regulatory. The University of Michigan (UM) has partnered with the Wallace H. Coulter Foundation (CF) to create a model providing an infrastructure to overcome these risks. This model is easily adoptable to other academic medical centers (AMCs). Clin Trans Sci 2010; Volume 3: 316–318 | en_US |
dc.format.extent | 1846645 bytes | |
dc.format.extent | 3106 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.subject.other | Valley of Death | en_US |
dc.subject.other | Translational Continuum | en_US |
dc.subject.other | Medical School Administration | en_US |
dc.subject.other | University-foundation Partnerships | en_US |
dc.subject.other | Pilot Programs | en_US |
dc.title | Successfully Accelerating Translational Research at an Academic Medical Center: The University of Michigan-Coulter Translational Research Partnership Program | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | The Michigan Institute for Clinical Research, the University of Michigan, Ann Arbor, Michigan, USA. | en_US |
dc.identifier.pmid | 21167009 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/79157/1/j.1752-8062.2010.00248.x.pdf | |
dc.identifier.doi | 10.1111/j.1752-8062.2010.00248.x | en_US |
dc.identifier.source | Clinical and Translational Science | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.